Review



anti mouse hrp dab cell tissue staining kit  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    R&D Systems anti mouse hrp dab cell tissue staining kit
    Anti Mouse Hrp Dab Cell Tissue Staining Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 15 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tissue+staining+kit/10__1302_slash_2046___3758__152__bjr___2024___0550__r2-67-19-26?v=R%26D+Systems
    Average 94 stars, based on 15 article reviews
    anti mouse hrp dab cell tissue staining kit - by Bioz Stars, 2026-07
    94/100 stars

    Images



    Similar Products

    90
    OriGene immunohistochemistry ihc staining kit
    Immunohistochemistry Ihc Staining Kit, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tissue+staining+kit/pm42208326-210-0-7?v=OriGene
    Average 90 stars, based on 1 article reviews
    immunohistochemistry ihc staining kit - by Bioz Stars, 2026-07
    90/100 stars
      Buy from Supplier

    94
    OriGene immunohistochemical staining kit
    Stromal CXCL12 associates with TLS enrichment in NSCLC-BM and improved outcomes with ICI therapy. (A) Bubble plots showing chemokine receptor expression levels in Microglia, B cells, and CD4-TCF1 T cells. (B) Bubble plots CXCL12 , CXCL13 , CCL19 , and CCL21 expression levels in NSCLC-BM samples. (C) Violin plots displaying the expression levels of CXCL12 and CXCL13 in tumours from TLS-low and TLS-high groups. TLS-low group, n = 12; TLS-high group, n = 13. P < 0.001 (∗∗∗). Dashed lines indicate the median and IQR. P -value was calculated using Mann–Whitney U test. P < 0.001 (∗∗∗). (D) Representative <t>IHC</t> images of CXCL12 staining in NSCLC-BM tissues. Scale bar = 100 μm. (E) The statistical results of CXCL12 IHC staining. Upper, Correlation between stromal CXCL12 expression and TLS scores.The stromal CXCL12 IRS scores of 0–6 were classified as low expression, whereas scores of 8–12 were classified as high expression. P -value was calculated using Pearson's chi-square test. Lower, the IRS of CXCL12 expression in paired stromal regions within and outside TLSs across 52 TLS-positive samples. Data are shown as individual values with mean ± SD. P -value was calculated using Wilcoxon test. (F) Bubble plot showing CXCL12 expression levels of different cell clusters. (G) Representative mIHC images of BM tissues stained with anti-CD20 (yellow), CD31 (red), FAP (magenta), and CXCL12 (green) antibodies. Upper, scale bar = 100 μm. Lower, scale bar = 10 μm. (H) Boxplots showing the fraction of CXCL12+ cells among CD31+ cells and FAP+ cells within TLSs across 52 TLS-positive samples. Data are presented as median with IQR. P -value was calculated using the Wilcoxon test. (I) Kaplan–Meier survival analysis for iPFS in patients with NSCLC-BM receiving postoperative ICIs (n = 29) according to CXCL12 IRS in intratumoral stroma. P -value was calculated using log-rank test. NSCLC-BM, non-small cell lung cancer brain metastasis; iPFS, intracranial progression-free survival; TLS, tertiary lymphoid structure; ICIs, immune checkpoint inhibitors; IRS, immunoreactivity scores.
    Immunohistochemical Staining Kit, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tissue+staining+kit/pmc13157008-100-11-14?v=OriGene
    Average 94 stars, based on 1 article reviews
    immunohistochemical staining kit - by Bioz Stars, 2026-07
    94/100 stars
      Buy from Supplier

    96
    Biosensis ltd brain tissues
    Stromal CXCL12 associates with TLS enrichment in NSCLC-BM and improved outcomes with ICI therapy. (A) Bubble plots showing chemokine receptor expression levels in Microglia, B cells, and CD4-TCF1 T cells. (B) Bubble plots CXCL12 , CXCL13 , CCL19 , and CCL21 expression levels in NSCLC-BM samples. (C) Violin plots displaying the expression levels of CXCL12 and CXCL13 in tumours from TLS-low and TLS-high groups. TLS-low group, n = 12; TLS-high group, n = 13. P < 0.001 (∗∗∗). Dashed lines indicate the median and IQR. P -value was calculated using Mann–Whitney U test. P < 0.001 (∗∗∗). (D) Representative <t>IHC</t> images of CXCL12 staining in NSCLC-BM tissues. Scale bar = 100 μm. (E) The statistical results of CXCL12 IHC staining. Upper, Correlation between stromal CXCL12 expression and TLS scores.The stromal CXCL12 IRS scores of 0–6 were classified as low expression, whereas scores of 8–12 were classified as high expression. P -value was calculated using Pearson's chi-square test. Lower, the IRS of CXCL12 expression in paired stromal regions within and outside TLSs across 52 TLS-positive samples. Data are shown as individual values with mean ± SD. P -value was calculated using Wilcoxon test. (F) Bubble plot showing CXCL12 expression levels of different cell clusters. (G) Representative mIHC images of BM tissues stained with anti-CD20 (yellow), CD31 (red), FAP (magenta), and CXCL12 (green) antibodies. Upper, scale bar = 100 μm. Lower, scale bar = 10 μm. (H) Boxplots showing the fraction of CXCL12+ cells among CD31+ cells and FAP+ cells within TLSs across 52 TLS-positive samples. Data are presented as median with IQR. P -value was calculated using the Wilcoxon test. (I) Kaplan–Meier survival analysis for iPFS in patients with NSCLC-BM receiving postoperative ICIs (n = 29) according to CXCL12 IRS in intratumoral stroma. P -value was calculated using log-rank test. NSCLC-BM, non-small cell lung cancer brain metastasis; iPFS, intracranial progression-free survival; TLS, tertiary lymphoid structure; ICIs, immune checkpoint inhibitors; IRS, immunoreactivity scores.
    Brain Tissues, supplied by Biosensis ltd, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tissue+staining+kit/pmc13038874-76-2-9?v=Biosensis+ltd
    Average 96 stars, based on 1 article reviews
    brain tissues - by Bioz Stars, 2026-07
    96/100 stars
      Buy from Supplier

    86
    Servicebio Inc bone tissue staining kit
    Stromal CXCL12 associates with TLS enrichment in NSCLC-BM and improved outcomes with ICI therapy. (A) Bubble plots showing chemokine receptor expression levels in Microglia, B cells, and CD4-TCF1 T cells. (B) Bubble plots CXCL12 , CXCL13 , CCL19 , and CCL21 expression levels in NSCLC-BM samples. (C) Violin plots displaying the expression levels of CXCL12 and CXCL13 in tumours from TLS-low and TLS-high groups. TLS-low group, n = 12; TLS-high group, n = 13. P < 0.001 (∗∗∗). Dashed lines indicate the median and IQR. P -value was calculated using Mann–Whitney U test. P < 0.001 (∗∗∗). (D) Representative <t>IHC</t> images of CXCL12 staining in NSCLC-BM tissues. Scale bar = 100 μm. (E) The statistical results of CXCL12 IHC staining. Upper, Correlation between stromal CXCL12 expression and TLS scores.The stromal CXCL12 IRS scores of 0–6 were classified as low expression, whereas scores of 8–12 were classified as high expression. P -value was calculated using Pearson's chi-square test. Lower, the IRS of CXCL12 expression in paired stromal regions within and outside TLSs across 52 TLS-positive samples. Data are shown as individual values with mean ± SD. P -value was calculated using Wilcoxon test. (F) Bubble plot showing CXCL12 expression levels of different cell clusters. (G) Representative mIHC images of BM tissues stained with anti-CD20 (yellow), CD31 (red), FAP (magenta), and CXCL12 (green) antibodies. Upper, scale bar = 100 μm. Lower, scale bar = 10 μm. (H) Boxplots showing the fraction of CXCL12+ cells among CD31+ cells and FAP+ cells within TLSs across 52 TLS-positive samples. Data are presented as median with IQR. P -value was calculated using the Wilcoxon test. (I) Kaplan–Meier survival analysis for iPFS in patients with NSCLC-BM receiving postoperative ICIs (n = 29) according to CXCL12 IRS in intratumoral stroma. P -value was calculated using log-rank test. NSCLC-BM, non-small cell lung cancer brain metastasis; iPFS, intracranial progression-free survival; TLS, tertiary lymphoid structure; ICIs, immune checkpoint inhibitors; IRS, immunoreactivity scores.
    Bone Tissue Staining Kit, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tissue+staining+kit/pmc13021455-81-8-12?v=Servicebio+Inc
    Average 86 stars, based on 1 article reviews
    bone tissue staining kit - by Bioz Stars, 2026-07
    86/100 stars
      Buy from Supplier

    94
    R&D Systems anti mouse hrp dab cell tissue staining kit
    Stromal CXCL12 associates with TLS enrichment in NSCLC-BM and improved outcomes with ICI therapy. (A) Bubble plots showing chemokine receptor expression levels in Microglia, B cells, and CD4-TCF1 T cells. (B) Bubble plots CXCL12 , CXCL13 , CCL19 , and CCL21 expression levels in NSCLC-BM samples. (C) Violin plots displaying the expression levels of CXCL12 and CXCL13 in tumours from TLS-low and TLS-high groups. TLS-low group, n = 12; TLS-high group, n = 13. P < 0.001 (∗∗∗). Dashed lines indicate the median and IQR. P -value was calculated using Mann–Whitney U test. P < 0.001 (∗∗∗). (D) Representative <t>IHC</t> images of CXCL12 staining in NSCLC-BM tissues. Scale bar = 100 μm. (E) The statistical results of CXCL12 IHC staining. Upper, Correlation between stromal CXCL12 expression and TLS scores.The stromal CXCL12 IRS scores of 0–6 were classified as low expression, whereas scores of 8–12 were classified as high expression. P -value was calculated using Pearson's chi-square test. Lower, the IRS of CXCL12 expression in paired stromal regions within and outside TLSs across 52 TLS-positive samples. Data are shown as individual values with mean ± SD. P -value was calculated using Wilcoxon test. (F) Bubble plot showing CXCL12 expression levels of different cell clusters. (G) Representative mIHC images of BM tissues stained with anti-CD20 (yellow), CD31 (red), FAP (magenta), and CXCL12 (green) antibodies. Upper, scale bar = 100 μm. Lower, scale bar = 10 μm. (H) Boxplots showing the fraction of CXCL12+ cells among CD31+ cells and FAP+ cells within TLSs across 52 TLS-positive samples. Data are presented as median with IQR. P -value was calculated using the Wilcoxon test. (I) Kaplan–Meier survival analysis for iPFS in patients with NSCLC-BM receiving postoperative ICIs (n = 29) according to CXCL12 IRS in intratumoral stroma. P -value was calculated using log-rank test. NSCLC-BM, non-small cell lung cancer brain metastasis; iPFS, intracranial progression-free survival; TLS, tertiary lymphoid structure; ICIs, immune checkpoint inhibitors; IRS, immunoreactivity scores.
    Anti Mouse Hrp Dab Cell Tissue Staining Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tissue+staining+kit/10__1302_slash_2046___3758__152__bjr___2024___0550__r2-67-19-26?v=R%26D+Systems
    Average 94 stars, based on 1 article reviews
    anti mouse hrp dab cell tissue staining kit - by Bioz Stars, 2026-07
    94/100 stars
      Buy from Supplier

    94
    OriGene two step staining kit
    Stromal CXCL12 associates with TLS enrichment in NSCLC-BM and improved outcomes with ICI therapy. (A) Bubble plots showing chemokine receptor expression levels in Microglia, B cells, and CD4-TCF1 T cells. (B) Bubble plots CXCL12 , CXCL13 , CCL19 , and CCL21 expression levels in NSCLC-BM samples. (C) Violin plots displaying the expression levels of CXCL12 and CXCL13 in tumours from TLS-low and TLS-high groups. TLS-low group, n = 12; TLS-high group, n = 13. P < 0.001 (∗∗∗). Dashed lines indicate the median and IQR. P -value was calculated using Mann–Whitney U test. P < 0.001 (∗∗∗). (D) Representative <t>IHC</t> images of CXCL12 staining in NSCLC-BM tissues. Scale bar = 100 μm. (E) The statistical results of CXCL12 IHC staining. Upper, Correlation between stromal CXCL12 expression and TLS scores.The stromal CXCL12 IRS scores of 0–6 were classified as low expression, whereas scores of 8–12 were classified as high expression. P -value was calculated using Pearson's chi-square test. Lower, the IRS of CXCL12 expression in paired stromal regions within and outside TLSs across 52 TLS-positive samples. Data are shown as individual values with mean ± SD. P -value was calculated using Wilcoxon test. (F) Bubble plot showing CXCL12 expression levels of different cell clusters. (G) Representative mIHC images of BM tissues stained with anti-CD20 (yellow), CD31 (red), FAP (magenta), and CXCL12 (green) antibodies. Upper, scale bar = 100 μm. Lower, scale bar = 10 μm. (H) Boxplots showing the fraction of CXCL12+ cells among CD31+ cells and FAP+ cells within TLSs across 52 TLS-positive samples. Data are presented as median with IQR. P -value was calculated using the Wilcoxon test. (I) Kaplan–Meier survival analysis for iPFS in patients with NSCLC-BM receiving postoperative ICIs (n = 29) according to CXCL12 IRS in intratumoral stroma. P -value was calculated using log-rank test. NSCLC-BM, non-small cell lung cancer brain metastasis; iPFS, intracranial progression-free survival; TLS, tertiary lymphoid structure; ICIs, immune checkpoint inhibitors; IRS, immunoreactivity scores.
    Two Step Staining Kit, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tissue+staining+kit/pm41494252-84-9-17?v=OriGene
    Average 94 stars, based on 1 article reviews
    two step staining kit - by Bioz Stars, 2026-07
    94/100 stars
      Buy from Supplier

    93
    OriGene 3 3 diaminobenzidine staining kit
    Stromal CXCL12 associates with TLS enrichment in NSCLC-BM and improved outcomes with ICI therapy. (A) Bubble plots showing chemokine receptor expression levels in Microglia, B cells, and CD4-TCF1 T cells. (B) Bubble plots CXCL12 , CXCL13 , CCL19 , and CCL21 expression levels in NSCLC-BM samples. (C) Violin plots displaying the expression levels of CXCL12 and CXCL13 in tumours from TLS-low and TLS-high groups. TLS-low group, n = 12; TLS-high group, n = 13. P < 0.001 (∗∗∗). Dashed lines indicate the median and IQR. P -value was calculated using Mann–Whitney U test. P < 0.001 (∗∗∗). (D) Representative <t>IHC</t> images of CXCL12 staining in NSCLC-BM tissues. Scale bar = 100 μm. (E) The statistical results of CXCL12 IHC staining. Upper, Correlation between stromal CXCL12 expression and TLS scores.The stromal CXCL12 IRS scores of 0–6 were classified as low expression, whereas scores of 8–12 were classified as high expression. P -value was calculated using Pearson's chi-square test. Lower, the IRS of CXCL12 expression in paired stromal regions within and outside TLSs across 52 TLS-positive samples. Data are shown as individual values with mean ± SD. P -value was calculated using Wilcoxon test. (F) Bubble plot showing CXCL12 expression levels of different cell clusters. (G) Representative mIHC images of BM tissues stained with anti-CD20 (yellow), CD31 (red), FAP (magenta), and CXCL12 (green) antibodies. Upper, scale bar = 100 μm. Lower, scale bar = 10 μm. (H) Boxplots showing the fraction of CXCL12+ cells among CD31+ cells and FAP+ cells within TLSs across 52 TLS-positive samples. Data are presented as median with IQR. P -value was calculated using the Wilcoxon test. (I) Kaplan–Meier survival analysis for iPFS in patients with NSCLC-BM receiving postoperative ICIs (n = 29) according to CXCL12 IRS in intratumoral stroma. P -value was calculated using log-rank test. NSCLC-BM, non-small cell lung cancer brain metastasis; iPFS, intracranial progression-free survival; TLS, tertiary lymphoid structure; ICIs, immune checkpoint inhibitors; IRS, immunoreactivity scores.
    3 3 Diaminobenzidine Staining Kit, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tissue+staining+kit/pmc13145336-25-18-21?v=OriGene
    Average 93 stars, based on 1 article reviews
    3 3 diaminobenzidine staining kit - by Bioz Stars, 2026-07
    93/100 stars
      Buy from Supplier

    93
    R&D Systems anti goat hrp dab cell tissue staining kit
    Stromal CXCL12 associates with TLS enrichment in NSCLC-BM and improved outcomes with ICI therapy. (A) Bubble plots showing chemokine receptor expression levels in Microglia, B cells, and CD4-TCF1 T cells. (B) Bubble plots CXCL12 , CXCL13 , CCL19 , and CCL21 expression levels in NSCLC-BM samples. (C) Violin plots displaying the expression levels of CXCL12 and CXCL13 in tumours from TLS-low and TLS-high groups. TLS-low group, n = 12; TLS-high group, n = 13. P < 0.001 (∗∗∗). Dashed lines indicate the median and IQR. P -value was calculated using Mann–Whitney U test. P < 0.001 (∗∗∗). (D) Representative <t>IHC</t> images of CXCL12 staining in NSCLC-BM tissues. Scale bar = 100 μm. (E) The statistical results of CXCL12 IHC staining. Upper, Correlation between stromal CXCL12 expression and TLS scores.The stromal CXCL12 IRS scores of 0–6 were classified as low expression, whereas scores of 8–12 were classified as high expression. P -value was calculated using Pearson's chi-square test. Lower, the IRS of CXCL12 expression in paired stromal regions within and outside TLSs across 52 TLS-positive samples. Data are shown as individual values with mean ± SD. P -value was calculated using Wilcoxon test. (F) Bubble plot showing CXCL12 expression levels of different cell clusters. (G) Representative mIHC images of BM tissues stained with anti-CD20 (yellow), CD31 (red), FAP (magenta), and CXCL12 (green) antibodies. Upper, scale bar = 100 μm. Lower, scale bar = 10 μm. (H) Boxplots showing the fraction of CXCL12+ cells among CD31+ cells and FAP+ cells within TLSs across 52 TLS-positive samples. Data are presented as median with IQR. P -value was calculated using the Wilcoxon test. (I) Kaplan–Meier survival analysis for iPFS in patients with NSCLC-BM receiving postoperative ICIs (n = 29) according to CXCL12 IRS in intratumoral stroma. P -value was calculated using log-rank test. NSCLC-BM, non-small cell lung cancer brain metastasis; iPFS, intracranial progression-free survival; TLS, tertiary lymphoid structure; ICIs, immune checkpoint inhibitors; IRS, immunoreactivity scores.
    Anti Goat Hrp Dab Cell Tissue Staining Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tissue+staining+kit/pmc12595481__pnas%2E2507092122%2Esapp-115-9-16?v=R%26D+Systems
    Average 93 stars, based on 1 article reviews
    anti goat hrp dab cell tissue staining kit - by Bioz Stars, 2026-07
    93/100 stars
      Buy from Supplier

    93
    OriGene two step immunohistochemical staining kit
    Stromal CXCL12 associates with TLS enrichment in NSCLC-BM and improved outcomes with ICI therapy. (A) Bubble plots showing chemokine receptor expression levels in Microglia, B cells, and CD4-TCF1 T cells. (B) Bubble plots CXCL12 , CXCL13 , CCL19 , and CCL21 expression levels in NSCLC-BM samples. (C) Violin plots displaying the expression levels of CXCL12 and CXCL13 in tumours from TLS-low and TLS-high groups. TLS-low group, n = 12; TLS-high group, n = 13. P < 0.001 (∗∗∗). Dashed lines indicate the median and IQR. P -value was calculated using Mann–Whitney U test. P < 0.001 (∗∗∗). (D) Representative <t>IHC</t> images of CXCL12 staining in NSCLC-BM tissues. Scale bar = 100 μm. (E) The statistical results of CXCL12 IHC staining. Upper, Correlation between stromal CXCL12 expression and TLS scores.The stromal CXCL12 IRS scores of 0–6 were classified as low expression, whereas scores of 8–12 were classified as high expression. P -value was calculated using Pearson's chi-square test. Lower, the IRS of CXCL12 expression in paired stromal regions within and outside TLSs across 52 TLS-positive samples. Data are shown as individual values with mean ± SD. P -value was calculated using Wilcoxon test. (F) Bubble plot showing CXCL12 expression levels of different cell clusters. (G) Representative mIHC images of BM tissues stained with anti-CD20 (yellow), CD31 (red), FAP (magenta), and CXCL12 (green) antibodies. Upper, scale bar = 100 μm. Lower, scale bar = 10 μm. (H) Boxplots showing the fraction of CXCL12+ cells among CD31+ cells and FAP+ cells within TLSs across 52 TLS-positive samples. Data are presented as median with IQR. P -value was calculated using the Wilcoxon test. (I) Kaplan–Meier survival analysis for iPFS in patients with NSCLC-BM receiving postoperative ICIs (n = 29) according to CXCL12 IRS in intratumoral stroma. P -value was calculated using log-rank test. NSCLC-BM, non-small cell lung cancer brain metastasis; iPFS, intracranial progression-free survival; TLS, tertiary lymphoid structure; ICIs, immune checkpoint inhibitors; IRS, immunoreactivity scores.
    Two Step Immunohistochemical Staining Kit, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tissue+staining+kit/pm40752035-86-7-11?v=OriGene
    Average 93 stars, based on 1 article reviews
    two step immunohistochemical staining kit - by Bioz Stars, 2026-07
    93/100 stars
      Buy from Supplier

    Image Search Results


    Stromal CXCL12 associates with TLS enrichment in NSCLC-BM and improved outcomes with ICI therapy. (A) Bubble plots showing chemokine receptor expression levels in Microglia, B cells, and CD4-TCF1 T cells. (B) Bubble plots CXCL12 , CXCL13 , CCL19 , and CCL21 expression levels in NSCLC-BM samples. (C) Violin plots displaying the expression levels of CXCL12 and CXCL13 in tumours from TLS-low and TLS-high groups. TLS-low group, n = 12; TLS-high group, n = 13. P < 0.001 (∗∗∗). Dashed lines indicate the median and IQR. P -value was calculated using Mann–Whitney U test. P < 0.001 (∗∗∗). (D) Representative IHC images of CXCL12 staining in NSCLC-BM tissues. Scale bar = 100 μm. (E) The statistical results of CXCL12 IHC staining. Upper, Correlation between stromal CXCL12 expression and TLS scores.The stromal CXCL12 IRS scores of 0–6 were classified as low expression, whereas scores of 8–12 were classified as high expression. P -value was calculated using Pearson's chi-square test. Lower, the IRS of CXCL12 expression in paired stromal regions within and outside TLSs across 52 TLS-positive samples. Data are shown as individual values with mean ± SD. P -value was calculated using Wilcoxon test. (F) Bubble plot showing CXCL12 expression levels of different cell clusters. (G) Representative mIHC images of BM tissues stained with anti-CD20 (yellow), CD31 (red), FAP (magenta), and CXCL12 (green) antibodies. Upper, scale bar = 100 μm. Lower, scale bar = 10 μm. (H) Boxplots showing the fraction of CXCL12+ cells among CD31+ cells and FAP+ cells within TLSs across 52 TLS-positive samples. Data are presented as median with IQR. P -value was calculated using the Wilcoxon test. (I) Kaplan–Meier survival analysis for iPFS in patients with NSCLC-BM receiving postoperative ICIs (n = 29) according to CXCL12 IRS in intratumoral stroma. P -value was calculated using log-rank test. NSCLC-BM, non-small cell lung cancer brain metastasis; iPFS, intracranial progression-free survival; TLS, tertiary lymphoid structure; ICIs, immune checkpoint inhibitors; IRS, immunoreactivity scores.

    Journal: eBioMedicine

    Article Title: TCF1+CD4+ T cells and microglia co-orchestrate tertiary lymphoid structures to enhance prognosis and immunotherapy in non-small cell lung cancer with brain metastases

    doi: 10.1016/j.ebiom.2026.106280

    Figure Lengend Snippet: Stromal CXCL12 associates with TLS enrichment in NSCLC-BM and improved outcomes with ICI therapy. (A) Bubble plots showing chemokine receptor expression levels in Microglia, B cells, and CD4-TCF1 T cells. (B) Bubble plots CXCL12 , CXCL13 , CCL19 , and CCL21 expression levels in NSCLC-BM samples. (C) Violin plots displaying the expression levels of CXCL12 and CXCL13 in tumours from TLS-low and TLS-high groups. TLS-low group, n = 12; TLS-high group, n = 13. P < 0.001 (∗∗∗). Dashed lines indicate the median and IQR. P -value was calculated using Mann–Whitney U test. P < 0.001 (∗∗∗). (D) Representative IHC images of CXCL12 staining in NSCLC-BM tissues. Scale bar = 100 μm. (E) The statistical results of CXCL12 IHC staining. Upper, Correlation between stromal CXCL12 expression and TLS scores.The stromal CXCL12 IRS scores of 0–6 were classified as low expression, whereas scores of 8–12 were classified as high expression. P -value was calculated using Pearson's chi-square test. Lower, the IRS of CXCL12 expression in paired stromal regions within and outside TLSs across 52 TLS-positive samples. Data are shown as individual values with mean ± SD. P -value was calculated using Wilcoxon test. (F) Bubble plot showing CXCL12 expression levels of different cell clusters. (G) Representative mIHC images of BM tissues stained with anti-CD20 (yellow), CD31 (red), FAP (magenta), and CXCL12 (green) antibodies. Upper, scale bar = 100 μm. Lower, scale bar = 10 μm. (H) Boxplots showing the fraction of CXCL12+ cells among CD31+ cells and FAP+ cells within TLSs across 52 TLS-positive samples. Data are presented as median with IQR. P -value was calculated using the Wilcoxon test. (I) Kaplan–Meier survival analysis for iPFS in patients with NSCLC-BM receiving postoperative ICIs (n = 29) according to CXCL12 IRS in intratumoral stroma. P -value was calculated using log-rank test. NSCLC-BM, non-small cell lung cancer brain metastasis; iPFS, intracranial progression-free survival; TLS, tertiary lymphoid structure; ICIs, immune checkpoint inhibitors; IRS, immunoreactivity scores.

    Article Snippet: IHC staining was performed using the SP method, employing the universal immunohistochemical staining kit (Zhongshan Golden Bridge Biotechnology; Cat# PV-6000) and DAB chromogen kit (Zhongshan Golden Bridge Biotechnology; Cat# PV-6000D).

    Techniques: Expressing, MANN-WHITNEY, Staining, Immunohistochemistry